CollPlant Biotechnologies Ltd. (CLGN)
| Previous Close | 7.30 |
| Open | 7.44 |
| Bid | 7.45 x 1000 |
| Ask | 7.77 x 1000 |
| Day's Range | 7.30 - 7.84 |
| 52 Week Range | 4.27 - 13.97 |
| Volume | |
| Avg. Volume | 16,691 |
| Market Cap | 85.312M |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.65 |
| Earnings Date | Nov 29, 2023 - Dec 04, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.92 |
PR NewswireCollPlant to Present at the H.C. Wainwright Annual Growth Conference
CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will participate at the H.C Wainwright Annual Growth Conference, to be held from September 11-13, 2023 in New York, NY. Eran Rotem, CollPlant's Deputy CEO and Chief Financial Officer, is scheduled to present on Tuesday, September 12th at 4:00 PM ET.
Simply Wall St.Results: CollPlant Biotechnologies Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts
CollPlant Biotechnologies Ltd. ( NASDAQ:CLGN ) just released its quarterly report and things are looking bullish...
PR NewswireCollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million
CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update on its programs.
